Novartis (NYSE:NVS – Get Free Report)‘s stock had its “neutral” rating reissued by investment analysts at UBS Group in a research report issued to clients and investors on Thursday, MarketBeat Ratings ...

She noted the survival benefit with the combination was achieved even though 38% of patients in the enzalutamide-alone arm ...

As detailed in our previous updates, the IRA’s Medicare Drug Price Negotiation Program (the Negotiation Program or Program), ...

Adding talazoparib (Talzenna) to enzalutamide (Xtandi) as initial treatment for metastatic castration-resistant prostate ...

At Novartis India, the focus on gender equality and the promotion of women in leadership roles is not just a corporate initiative—it's a commitment ingrained in the organisation's culture. Speaking to ...